Viyash Scientific Limited (VIYASH) Fair Value & Analysis
Healthcare · IN · Market cap ₹128B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price +18.6% over the past month.
Price vs Fair Value (6 months)
6‑month range ₹178.85 – ₹292.45 · fair‑value band ₹60.93 – ₹101.54 · the ₹292.45 price screens above the ₹81.23 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Viyash Scientific Limited (VIYASH) currently trades at ₹292.45, while our model-based Fair Value estimate is ₹81.23 — implying the stock looks roughly 72.2% overvalued today. We read business quality at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Viyash Scientific Limited generated revenue of ₹34.2B at a net margin of 5.2%. Revenue grew 129.0% year over year. It earns a return on equity of 11.6%. Net debt stands at ₹2.2B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services. The company was formerly known as Sequent Scientific Limited and changed its name to Viyash Scientific Limited in January 2026. The company was incorporated in 1985 and is headquartered in Hyderabad, India. Viyash Scientific Limited operates as a subsidiary of CA Harbor Investments.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Viyash Scientific Limited reported revenue of ₹34.2B in FY2026 versus ₹14.1B in FY2022, a compound +24.8%/yr. Reported net income was ₹1.8B in FY2026, compounding +44.2%/yr from FY2022.
Is VIYASH fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Viyash Scientific Limited (VIYASH) undervalued?
What is the fair value of VIYASH?
What is the quality score of VIYASH?
What is the revenue of Viyash Scientific Limited (VIYASH)?
What is the net profit margin of VIYASH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.